# 3 Non-Controlled

**Page range:** 19–19

```text
3. Non-Controlled
BO42864
(AcceleRET-
Lung)
A phase III, randomized, open-label study of
pralsetinib versus standard of care for first-
line treatment of RET fusion−positive,
metastatic non−small cell lung cancer
Phase III
```